UK Committee Attacks Pharma Over Lack Of Medicinal Cannabis Research
The pharmaceutical industry has come under attack by a UK parliament committee for failing to make medicinal cannabis products available for clinical trials, saying that a "robust research base" is needed on which to base future treatment decisions.
You may also be interested in...
Four drugs are up for an opinion this week on whether they should be granted EU-wide approval, including Amgen/UCB's osteoporosis drug romosozumab.
In case you have not noticed, a new gold rush appears to be under way. Buoyed by surging interest in medical cannabis, big and small companies from around the world are racing to take advantage of the potential for the marijuana plant to cure numerous diseases and take its place in the pantheon of pharmaceutical products.
With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.